A novel combination therapy cures an emerging infectious disease, babesiosis, which is transmitted by the same ticks that transmit the agents of Lyme disease, said Yale researchers. This "radical" therapy not only clears the infection but also prevents the recurrence that often occurs with existing treatments.
The study was published online June 6 in the Journal of Experimental Medicine.
Babesiosis is caused by the B. microti parasite, which is most often transmitted through tick bites. It is more common in the Northeast and northern Midwestern states, and likely is on the rise as infected ticks expand geographically. Infected individuals can be asymptomatic, or develop symptoms that range from mild and flu-like to severe and life threatening. The parasite can develop resistance to existing therapies, leading to relapses after treatment.
For their study, the Yale-led team first tested in mice with diminished immune systems four drugs that are currently used in the form of two combinations to treat human babesiosis. Only one of those drugs, atovaquone, was effective in attacking a target enzyme that, when mutated, allows the parasite to develop resistance. Using the mouse model, the team observed efficacy with a fifth drug (ELQ) that involves a similar mechanism of action as atovaquone but at a different enzyme target site. They decided to test the two drugs in combination.
The researchers found that the combination of atovaquone and ELQ-334, at low doses, cleared the infection and prevented recurrence up to 122 days after treatment.
"This is the first radical cure against this parasite," said Choukri Ben Mamoun, associate professor of infectious diseases. "The novelty of the study was identifying a combination therapy that will both kill the parasite and also paralyze the target enzyme, making it nearly impossible for the parasite to develop resistance."
The finding is significant since babesiosis is increasing and up to 19 percent of the ticks and up to 42 percent of the mammalian hosts (mice and other rodents) that carry the bacteria that cause Lyme disease is co-infected with B. microti.
With this finding, Ben Mamoun and his co-authors can take the next step and pursue studies of the combination therapy in people. "We are developing a better analog for ELQ that will be used in clinical trials. That's what our future studies will focus on -- identifying a better ELQ that could be added to atovaquone. We could test the safety of the compound in humans," he said.
Other study authors include Lauren A. Lawres, Aprajita Garg, Vidya Kumar, Igor Bruzual, Isaac P. Forquer, Isaline Renard, Azan Z. Virji, Pierre Boulard, Eduardo X. Rodriguez, Alexander J. Allen, Sovitj Pou, Keith W. Wegmann, Rolf W. Winter, Aaron Nilsen, Jialing Mao, Douglas A. Preston, Alexia A. Belperron, Linda K. Bockenstedt, David J. Hinrichs, Michael K. Riscoe, and J. Stone Doggett.
The research was supported by the National Institutes of Health and the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development.
Source: Yale University
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.